Silence Therapeutics (SLN) Quiet Q3, Loud Merck KGaA Tie-Up: A Cash-Rue, Pipeline-First Play

Executive snapshot

ticker SLN, Nasdaq-listed Silence Therapeutics, reports its third-quarter 2026 results with a focus on liquidity, cost discipline, and a strategic porcupine of catalysts. The company posted a GAAP EPS of negative $0.08 for the quarter (basic and diluted), as net loss narrowed to $12.4 million from $21.0 million a year earlier. Cash and cash equivalents stood at $247.7 million as of September 30, 2026, bolstered by $201.3 million gross proceeds from an upsized offering announced on August 11, 2026. Total outstanding ordinary shares were 186,609,073 at the period end.

Note the press release does not present a revenue forecast, and there is no published EPS consensus or explicit earnings surprise data in the release. Still, the quarterly numbers imply ongoing operating burn in a clinical-stage outfit and a more favorable cash runway than a year ago, even as development costs ebb.

Recent business highlights and near-term catalysts

Silence’s SANRECO Phase 2 data for divesiran, a TMPRSS6-targeting siRNA therapy, produced topline results described as supportive of a potential best-in-class profile with once-every-three-month dosing in polycythemia vera. The company announced that SANRECO Phase 2 results have been accepted for oral presentation at the American Society of Hematology (ASH) 2026 Annual Meeting (Dec 12–15, 2026, New Orleans). Presentation details are accessible via the company’s materials.

On October 19, 2026, Silence disclosed a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The transaction is expected to close in the first quarter of 2027, subject to customary closing conditions. The deal adds strategic context to Silence’s pipeline and suggests a potential value inflection for investors should the transaction progress toward closing.

Third Quarter 2026 financial highlights

Cash position: Cash and cash equivalents were $247.7 million as of September 30, 2026, including $201.3 million in gross proceeds from the August upsized offering.

R&D expenses: $9.3 million for the three months ended September 30, 2026, versus $20.5 million for the prior-year quarter. The decrease is attributed to the completion of zerlasiran Phase 3 readiness in 2025 and reduced personnel costs.

G&A expenses: $4.9 million for the three months ended September 30, 2026, down from $5.8 million in the prior-year quarter, driven by efforts to trim administrative costs.

Net loss and EPS: Net loss of $12.4 million, or $0.08 per basic and diluted share, for the three months ended September 30, 2026, versus a net loss of $21.0 million, or $0.15 per share, in the prior-year quarter.

Shares outstanding: Total outstanding ordinary shares were 186,609,073 as of September 30, 2026 (including ADS).

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company focused on silencing disease-causing genes using proprietary siRNA (short interfering RNA) technology. The company leverages its mRNAi GOLD® platform to develop therapies aimed at high unmet-need diseases across rare and common indications. For more information, visit https://www.silence-therapeutics.com/.

What this could portend for Silence and its peers

The Q3 narrative skews toward balance-sheet resilience and near-term catalysts, rather than immediate profitability. The cash runway extension—supported by the upsized equity raise—gives Silence time to advance SANRECO’s topline data presentation and await potential inflections tied to the ASH conference data and the Merck KGaA deal.

The acquisition talks inject a structural premium into Silence’s equity story, but the closing risk remains until regulatory and shareholder approvals clear and the customary conditions are satisfied. For sector peers in the siRNA and broader gene-silencing field, the Silence-Merck KGaA development underscores one recurring theme: strategic alternatives and M&A may increasingly shape valuations as early-stage pipelines approach meaningful data milestones.

For investors, several practical angles emerge. First, the quarterly EPS and the negative but narrowing loss highlight that “earnings surprise” expectations, if any, are less about quarterly beats and more about data milestones and the sustainability of cash burn. The absence of a stated EPS consensus or explicit revenue forecast in the release means markets will be leaning on near-term catalysts—ASH data, a potential deal close, and any guidance around the pipeline.

In a world where the public markets have grown more discerning of clinical-stage risk, Silence’s combination of a clear strategic partner, a tangible delivery cadence (three-month dosing), and a measurable cash runway could position it as a case study for peers weighing licensing, collaboration, or takeout options rather than chasing independent value unfettered by liquidity concerns.

Bottom line

Silence Therapeutics’ Q3 2026 results present a biotech in transition: controlled burn on R&D and admin costs, a cash buffer that supports continued data generation, and a potential strategic pivot through a Merck KGaA acquisition. The combination of SANRECO Phase 2 data with an active near-term M&A backdrop makes Silence a stock to watch not for immediate earnings headlines, but for the risk-adjusted value inflection that may come from data milestones and deal dynamics across the sector.